SAN JOSE, Calif., Dec. 6, 2017 /PRNewswire/ -- ITUS
Corporation (NASDAQ: ITUS) today announced that its abstract
titled, "The coupling of MDSCs with a computational analytic
method to detect solid tumors," was accepted for presentation
at the 2nd annual American Society of Clinical
Oncology-Society for Immunotherapy of Cancer (ASCO-SITC) Clinical
Immuno-oncology Symposium in San
Francisco, CA. Myeloid-derived suppressor cells, or MDSCs,
are a key group of white blood cells that form the foundation for
ITUS' liquid biopsy technology.
The presentation will focus on ITUS' proprietary Cchek™ platform
which couples immuno-oncology and artificial intelligence
technologies to enable the detection of solid tumors from a blood
sample. Contributing authors are Dr. Amit Kumar, Dr. George
Dominguez, John Roop,
Anthony Campisi, and Cyrus Sholevar of ITUS Corporation along with
Alexander Polo, Dr. Dmitry Gabrilovich, and Dr. Frank Rauscher III, from The Wistar
Institute.
"As discussed in recent public announcements, over the coming
months we plan to increase our profile with the oncology scientific
community, as well as the broader investment and biotechnology
industry, via presentations of data and development status of our
technologies. ASCO-SITC is an ideal place for us to begin the
new year with an updated data presentation," stated Dr.
Amit Kumar, President and CEO of
ITUS Corporation.
The symposium will be held on January
25-27, 2018, and will be attended by the leading scientific
minds in the field of immuno-oncology from across the world.
All abstracts for the Symposium are currently confidential, but
will be released by ASCO on January 22,
2018 at 5:00 PM EST on
abstracts.asco.org. To receive a copy of the presentation,
please send your request to ASCO-SITC-2018@ITUScorp.com after
January 26, 2017 and include your
name, title, and contact information.
ASCO-SITC
The ASCO-SITC Clinical Immuno-Oncology Symposium
(https://immunosym.org) is a three-day meeting focused on clinical
and translational research in immuno-oncology and the implications
for clinical care.
ASCO (www.asco.org) was founded in 1964 and is the world's
leading professional organization for physicians and oncology
professionals caring for people with cancer.
SITC (www.sitcancer.org) was found in 1984 and is the world's
leading member-driven organization specifically dedicated to
improving cancer patient outcomes by advancing the science and
application of cancer immunotherapy.
ITUS Corporation
ITUS, a cancer-focused biotechnology company, is harnessing the
body's immune system in the fight against cancer. Its wholly
owned subsidiary, Anixa Diagnostics Corporation, is developing the
CchekTM platform, a series of non-invasive blood tests
for the early detection of solid tumor based cancers, which is
based on the body's immunological response to the presence of a
malignancy. Its majority owned subsidiary, Certainty
Therapeutics, Inc., is developing CAR-T based immuno-therapy drugs
which genetically engineer a patient's own immune cells to fight
cancer. ITUS also continually examines emerging technologies
in complementary or related fields for further development and
commercialization. Additional information is available at
www.ITUScorp.com.
Forward-Looking Statements: Statements that are
not historical fact may be considered forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements are not statements of
historical facts, but rather reflect ITUS Corporation's current
expectations concerning future events and results. We generally use
the words "believes," "expects," "intends," "plans," "anticipates,"
"likely," "will" and similar expressions to identify
forward-looking statements. Such forward-looking statements,
including those concerning our expectations, involve risks,
uncertainties and other factors, some of which are beyond our
control, which may cause our actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance, or achievements expressed or
implied by such forward-looking statements. These risks,
uncertainties and factors include, but are not limited to, those
factors set forth in "Item 1A - Risk Factors" and other sections of
our most recent Annual Report on Form 10-K as well as in our
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We
undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law. You are
cautioned not to unduly rely on such forward-looking statements
when evaluating the information presented in this press
release.
ITUS Corporation: FOCUSED ON INNOVATION™
View original content with
multimedia:http://www.prnewswire.com/news-releases/itus-will-present-data-on-early-cancer-detection-technology-at-asco-sitc-symposium-300567077.html
SOURCE ITUS Corporation